Skip to main content
FERMENTA BIOTECH LIMITED logo

FERMENTA BIOTECH LIMITED — Investor Relations & Filings

Ticker · FERMENTA ISIN · INE225B01021 LEI · 335800VNTNWW8G1U9314 BSE.NS Manufacturing
Open in API
Filings indexed 670 across all filing types
Latest filing 2025-12-10 Capital/Financing Update
Country IN India
Listing BSE.NS FERMENTA

About FERMENTA BIOTECH LIMITED

https://fermentabiotech.com

Fermenta Biotech Limited is a specialized biotechnology company primarily focused on the development and manufacture of Vitamin D3 (Cholecalciferol). As one of the few vertically integrated manufacturers globally, the company produces Vitamin D3 for diverse applications, including pharmaceuticals, dietary supplements, human nutrition, and animal feed. Beyond its core Vitamin D3 portfolio, the company offers a range of specialty enzymes, particularly for the synthesis of beta-lactam antibiotics, and provides environmental solutions through its biotechnology expertise. Fermenta Biotech emphasizes high-quality standards, maintaining various international certifications for its manufacturing facilities. Its product offerings extend to premixes and value-added formats designed to meet specific formulation requirements. The company serves a global clientele, leveraging its research and development capabilities to innovate in the fields of nutrition and biotechnology.

Recent filings

Filing Released Lang Actions
Update on capacity addition at Dahej facility.
Capital/Financing Update Classification · 95% confidence The document is an official communication addressed to the stock exchange (BSE Limited) under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. It announces the Board of Directors' approval of a capital expenditure (capex) plan of INR 110 crore for capacity addition at the company's existing facility. The document includes detailed disclosures as per regulatory requirements, including investment amount, rationale, financing mode, and timelines. It also contains a press release elaborating on the strategic rationale and business implications of the investment. The document is not a full financial report, audit report, earnings release, or management discussion and analysis. It is a regulatory announcement informing the market about a significant capital expenditure decision by the Board. Therefore, it fits best under the category of Capital/Financing Update (CAP). The document length (over 12,000 characters) and detailed content confirm it is not a mere announcement of a report (RPA) or a short regulatory filing (RNS).
2025-12-10 English
Fermenta Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/12/2025 ,inter alia, to consider and approve the proposal for raising of funds.
Capital/Financing Update Classification · 95% confidence The document is a notice of a Board Meeting scheduled to consider a proposal for raising funds through issuance of various securities. It is a formal announcement pursuant to a regulatory requirement (Regulation 29 of SEBI Listing Regulations) informing the stock exchange about the upcoming board meeting and its agenda related to capital raising. The document does not contain financial data, results, or detailed reports but is an announcement of a meeting and its agenda. Therefore, it fits the category of Capital/Financing Update (CAP). The document length is short and it is not a report publication announcement or certification. Hence, the classification is CAP with high confidence.
2025-12-07 English
Intimation of investor meeting.
Regulatory Filings Classification · 95% confidence The document is a short notice informing the stock exchange about an upcoming investor meeting. It references a previously released press release and investor presentation related to unaudited financial results for the half year ended September 30, 2025, but does not contain any financial data itself. The document is an announcement of an event (investor meeting) and references other materials rather than being a report or detailed financial disclosure. It is also under 5,000 characters and serves as a regulatory communication under SEBI regulations. Therefore, it fits best under Regulatory Filings (RNS) as a general regulatory announcement rather than a financial report or presentation.
2025-12-02 English
Investor presentation H1/FY26
Investor Presentation Classification · 100% confidence The document is titled as an "Investor Presentation – H1/FY26" and is explicitly described as an investor presentation for the half-year period ending FY26. It contains detailed financial highlights, segment performance, cash flow statements, cost breakdowns, performance ratios, customer concentration, and strategic business information. The document is about 15,000 characters long, which is consistent with a detailed presentation rather than a brief announcement. It is not a full annual or interim report with comprehensive financial statements but rather a presentation summarizing financial and operational performance for investors. The text also references uploading the presentation to the company website and submission pursuant to SEBI regulations, which is typical for investor presentations. Therefore, the document fits the category of an Investor Presentation (IP).
2025-11-12 English
Publication of unaudited financial results for the quarter and half year ended September 30, 2025.
Regulatory Filings
2025-11-12 English
Press release with respect to financial results of H1FY26
Interim / Quarterly Report Classification · 95% confidence The document is a press release issued by Fermenta Biotech Limited announcing financial results for the half year ended September 30, 2025 (H1FY26). It contains detailed financial highlights such as consolidated revenue, EBITDA, profit after tax, EPS, segment-wise revenue, and geographical revenue mix. The document also includes management commentary on the results and strategic business updates like the transfer of a business division and patent grant. The document is about 9,620 characters long, which is substantial and contains actual financial data and analysis for a half-year period. This fits the definition of an Interim / Quarterly Report (IR), which is a comprehensive financial report for a period shorter than a full fiscal year with substantive financial data and analysis. It is not merely an announcement or a brief summary, nor is it a full annual report or earnings release with only key highlights. Therefore, the appropriate classification is Interim / Quarterly Report (IR).
2025-11-11 English

Browse filings by year

8 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.